Objectives: The aim of this study was to evaluate the occurrence and dissemination of acquired carbapenem-hydrolysing class D b-lactamase (class D carbapenemase)-and metallo-b-lactamase (MBL)-encoding genes among Acinetobacter spp. isolates recovered from medical centres in the AsiaPacific (APAC) region.
Introduction
Acinetobacter spp. are opportunistic pathogens, frequently associated with immunosuppressed patients as well as those with serious underlying diseases or subjected to invasive procedures and treated with broad-spectrum antimicrobial agents. 1 During the past decade, several reports have described the association of these pathogens with numerous outbreaks, 2 mainly in intensive care units. This corresponds with the emergence of resistance to nearly all clinically used classes of antimicrobial agents on a worldwide scale. 3 As such, carbapenems are important therapeutic options for treating infections caused by Acinetobacter spp.; however, these antimicrobial agents may be hydrolysed by Ambler class B metallo-b-lactamases (MBLs) as well as by carbapenem-hydrolysing class D b-lactamases (class D carbapenemase). 4 Six groups of acquired MBL-encoding genes have been identified; 5 however, only bla IMP -and bla VIM -like, and more recently bla SIM-1 , have been reported in Acinetobacter spp. 4 IMP variants have been described in several Far Eastern countries, including Japan, China (Hong Kong), South Korea and Australia, while VIM variants have rarely been detected in those nations. 4 Conversely, acquired class D carbapenemase-encoding genes have been more frequently detected in Acinetobacter spp. 1 and are clustered in three major subfamilies, bla OXA-23 -, bla OXA-24 -and bla OXA-58 -types. 6 Given the presence of these resistance determinants within mobile elements and the genetic potential of Acinetobacter spp. for acquiring foreign DNA from the environment, 1 intensive surveillance to assist infection control interventions has become very important to minimize the dissemination of resistant isolates and/or resistance genes. The objective of this surveillance study was to evaluate the occurrence and dissemination of acquired class D carbapenemase-and MBL-encoding genes among Acinetobacter spp. isolates recovered from medical centres in the Asia-Pacific (APAC) region.
Materials and methods

Bacterial isolates
During 2006-07, 41 medical centres located in 10 countries in the APAC region were recruited to participate in the SENTRY Antimicrobial Surveillance Program. A total of 544 isolates were consecutively collected from bloodstream, respiratory tract, skin and skin structure and urinary tract infections, according to defined protocols, from Republic of China (182 isolates), India (132), Indonesia (67), Thailand (48), Korea (47), Taiwan (24), Singapore (21), Australia (9), Hong Kong (8) and the Philippines (6). Only isolates responsible for documented infections were included in the study; one per patient episode. Species identification was performed by standard biochemical tests and by use of the Vitek system (bioMérieux, Hazelwood, MO, USA), when necessary. Additionally, species identification was confirmed by sequencing of the 16S ribosomal RNA gene on those isolates showing negative PCR results for bla OXA-51/69 -like. 6 Antimicrobial susceptibility testing All isolates were tested for susceptibility and the results were interpreted as described previously. 3 Tigecycline MIC results were interpreted according to the breakpoints for Enterobacteriaceae approved by the United States Food and Drug Administration (USA-FDA; breakpoint for susceptibility, 2 mg/L; breakpoint for resistance, 8 mg/L). 3 Escherichia coli ATCC 25922 and Pseudomonas aeruginosa ATCC 27853 were concurrently tested for quality control purposes; all results were within published ranges.
Class D carbapenemase-and MBL-encoding genes detection
Isolates non-susceptible to imipenem or meropenem (MIC, 8 mg/L) were screened using primers able to detect and distinguish alleles encoding three subfamilies of acquired class D carbapenemase (bla OXA-23 -like, bla OXA-24/40 -like and bla OXA-58 -like) and the intrinsic subgroup of bla OXA-51/69 -like (Acinetobacter baumannii) genes in a multiplex PCR assay format. 6 MBL screening was performed using generic primers able to detect VIM-and IMP-like, SPM-1-, GIM-1-and SIM-1-encoding genes in a multiplex real-time platform. 7 Positive controls for all screened genes were run simultaneously. Amplicons were sequenced on both strands.
The nucleotide sequences and deduced amino acid sequences were analysed using the Lasergene software package (DNASTAR, Madison, WI, USA) and compared with the sequences available through the internet using BLAST (http://www.ncbi.nlm.nih.gov/blast/).
Molecular typing
Clinical isolates recovered within each medical centre that harboured carbapenemase-encoding genes were typed using the Riboprinter TM Microbial Characterization system (DuPont Qualicon, Wilmington, DE, USA). Isolates showing identical ribotypes were further characterized by PFGE, as described previously. 8 Gel pattern analysis was carried out using the GelCompar II software (Applied Math, Kortrijk, Belgium). Percentage similarities were identified on a dendrogram derived from the unweighted pair group method using arithmetic averages and based on Dice coefficients. Band position tolerance and optimization were set at 1.3% and 0.5%, respectively. 8 Isolates showing a similarity coefficient of .80% were considered as genetically related for this study. The PFGE pattern was determined based on the number of the medical centre followed by a capital letter (A, B, C). Isolates were assigned with the same PFGE pattern when the similarity coefficient was 100%. When this coefficient was in between 80% and 100%, the isolates were assigned as a subtype or variant of the major type, which was designated with the same capital letter followed by an Arabic number (e.g. C1, C2, C3).
Results
Bacterial isolates and antimicrobial susceptibility profile
A total of 544 Acinetobacter spp. isolates were recovered during 2006 -07 from medical centres located in the APAC region. The vast majority were identified as A. baumannii (94.1%), followed by a lower prevalence of Acinetobacter junii (2.8%), Acinetobacter lwoffii (1.8%), Acinetobacter haemolyticus (0.4%), Acinetobacter johnsonii (0.2%), Acinetobacter calcoaceticus (0.2%) and Acinetobacter radioresistens (0.2%). Two isolates could not be identified to the species level (0.4%). Polymyxins (99.1% susceptible) and glycylcyclines (tigecycline; 98.9% of isolates showed MIC 2 mg/L) were the most active antimicrobial agents tested, followed by the carbapenems, imipenem and meropenem (52.0% and 51.3% susceptible, respectively). The remaining antimicrobials evaluated showed activity at 41.2%. Among the isolates, 230 (42.3%) were non-susceptible (MIC 8 mg/L) to imipenem or meropenem, and this resistance phenotype was most common in isolates recovered from Singapore (95.2%), Korea (87.0%), Taiwan (62.5%), Thailand (59.2%) and Hong Kong (50.0%).
Class D carbapenemase-and MBL-encoding genes
Among the carbapenem non-susceptible isolates, class D carbapenemase-and MBL-encoding genes were detected in 70.0% (160 isolates) and 0.8% of the isolates (two isolates), respectively. bla OXA-23 was the most common gene, which accounted for 95.0% of the class D carbapenemase-encoding genes detected, followed by a lower occurrence of bla OXA-58 (11.9%) and bla OXA-24/40 (5.6%). bla OXA-23 was found in isolates distributed among six nations (Table 1) , which included all nations participating in the SENTRY Program (APAC), except Australia and Indonesia; while bla OXA-24/40 was detected only in isolates recovered from Taiwan, Thailand and Indonesia, and bla OXA-58 was detected in isolates recovered from China, India and Thailand. Several isolates harbouring more than one class D carbapenemase-encoding gene were found in China (bla OXA-23 plus bla OXA-58 ) and Thailand (bla OXA-24/40 plus bla OXA-58 , and bla OXA-23 plus bla OXA-24/40 plus bla OXA-58 ; Table 1 ), including an A. radioresistens clinical isolate recovered from India harbouring bla OXA-58 in addition to the intrinsic bla OXA-23 -like. 9 Sequencing results of this intrinsic gene revealed the presence of a novel variant, named bla OXA-133 (accession no. EU571228). MBL-encoding genes were detected in one A. johnsonii recovered from the Philippines (bla IMP-4 ) and one A. baumannii recovered from Korea (bla VIM-2 ). Figure 1 shows a dendrogram containing representative isolates belonging to each dominant clone within each medical site and according to carbapenemase production. bla OXA-23 -carrying A. baumannii representative isolates belonging to clones ACB-252-B and ACB-248-G recovered from different medical sites in India were considered genetically related (similarity coefficient of 82.8%). Similar findings were noted with bla OXA-23 -carrying A. baumannii belonging to clones ACB-218-A and ACB-238-A recovered from two medical sites located in Beijing, China (similarity coefficient of 86.7%). bla OXA-24/40 -carrying A. baumannii belonging to clone ACB-223-A isolated from Taiwan clustered with bla OXA-23 -carrying A. baumannii belonging to clones ACB-225-B and ACB-217-A recovered from Korea and Singapore (similarity coefficient 85.7%; Figure 1 ), respectively, and these isolates also showed the same ribogroup. In addition, the representative isolate harbouring bla OXA-24/40 from Thailand (226-24-A) clustered with the representative isolate harbouring bla OXA-23 from Hong Kong (similarity coefficient of 82.4%; Figure 1 ). The isolate harbouring bla OXA-24/40 and bla OXA-58 from Thailand was clustered with OXA-23-, OXA-24/40-and OXA-58-producing A. baumannii recovered from the same medical site (ACB-226-A; Figure 1 ). Genetic relatedness was not found among other minor clones.
Molecular typing
Discussion
Overall, this study showed low susceptibility rates to most of the clinically available antimicrobial agents for the treatment of infections caused by Acinetobacter spp., except for polymyxin B and the novel glycylcycline, tigecycline, which may represent valuable antimicrobial options for the treatment of infections caused by these isolates. 3 Among those isolates showing a resistant phenotype towards imipenem, 75.4% harboured at least one acquired class D carbapenemase-encoding gene, while among those isolates showing intermediate resistance towards this drug, only 11.1% harboured an acquired gene (data not shown). Therefore, the high prevalence of class D carbapenemase-encoding genes among the clinical isolates from the APAC region appears responsible for low susceptibility rates for imipenem [P , 0.001; OR ¼ 0.04 (0.01 -0.20)].
Recently, Zhou et al. 2 reported that 94.2% of imipenemresistant A. baumannii isolates from China harboured bla OXA-23 , while Wang et al. 10 described that 97.7% and 4.1% of the imipenem-resistant Acinetobacter spp. isolates harboured bla OXA-23 and bla OXA-58 , respectively. In this study, bla OXA -carrying Acinetobacter spp. represented 68.2% (30 of 44) of imipenem-resistant isolates from China. Among these isolates, 90.0% (27 of 30) and 46.6% (14 of 30) harboured bla OXA-23 and bla OXA-58 , respectively. However, among the isolates harbouring bla OXA-23 , 40.7% (11 of 27) also possessed bla OXA-58 , suggesting that the epidemiology of class D carbapenemase-encoding genes has significantly changed in Acinetobacter spp. clinical isolates recovered from China.
Two clusters (ACB-252-B and ACB-248-G) considered genetically related (similarity coefficient of 82.8%) were noted in two different cities in India. However, clonal dissemination within each medical centre was predominantly observed, suggesting that the isolates from this study mostly belonged to local clones causing sporadic or endemic outbreaks within each medical institution. Previously published reports have shown clonal dissemination of OXA-23-producing A. baumannii among several medical centres located in different cities in China, 2, 10 which contrasts with our findings. In this study, only the clones ACB-218-A and ACB-238-A, considered genetically related, were noted in different institutions from China (similarity coefficient of 86.7%); however, these medical centres were located in the same city (Beijing). These contrasting results may have been due to the fact that the carbapenem-resistant isolates from this study were recovered from a smaller number of medical centres and cities other than those included in those previous studies. 11 bla IMP-4 has been previously detected in Acinetobacter spp. and Citrobacter youngae from China, and subsequently, bla IMP-4 -carrying P. aeruginosa emerged and this resistance gene rapidly disseminated among several Gram-negative pathogens in an Australian hospital setting. 5 Although the prevalence of MBL genes was very low in our study, the detection of a bla IMP-4 -carrying A. johnsonii recovered from a patient in the Philippines underscores the continued spread of this gene in the geographic region. This highlights the importance of active hospital surveillance to avoid possible infection outbreaks by such organisms. 5 Furthermore, there have been only a few detections of VIM variants in Acinetobacter spp. in the APAC region, predominantly represented by the occurrence of bla VIM-2 in South Korea, 4 and our study highlights the continued detection of this determinant in that country, albeit at low frequency.
The presence of multiple class D carbapenemase-encoding genes in single isolates was noted in China, India and Thailand (Table 1) . Additionally, the detection of an A. radioresistens clinical isolate carrying the intrinsic bla OXA-23 -like and bla OXA-58 emphasizes (i) the natural occurrence of class D carbapenemaseencoding genes among Acinetobacter species, 4, 9 (ii) the ability for acquiring and/or exchanging foreign DNA, 1 and (iii) the diversity of resistance genes in the hospital environment. These findings also provide strong evidence that the hospital environment has become the main reservoir of these resistance determinants, 9 which may facilitate DNA exchange among endemic nosocomial pathogens.
